Journal of pharmacy practice最新文献_第7页

Utilization of the PEN-FAST Clinical Decision-Making Tool to Update Penicillin Allergies and Identify Low-Risk Patients. 利用 PEN-FAST 临床决策工具更新青霉素过敏症并识别低风险患者。

IF 1

Journal of pharmacy practice Pub Date : 2024-11-19 DOI: 10.1177/08971900241302394

Hien Lam, Katie Parsels, Jeffrey M Steele, Wesley D Kufel, Ryan Andrew, Christopher Miller, William Darko, Robert Seabury

引用次数: 0

Evaluation of Pharmacist-led Telehealth Medicare Annual Wellness Visits to Satisfy Quality Metrics and USPSTF Recommendations After Implementation of a Post-Visit Follow-Up Protocol. 评估药剂师主导的远程健康医疗保险年度健康访视在实施访视后随访协议后是否符合质量指标和 USPSTF 建议。

IF 1

Journal of pharmacy practice Pub Date : 2024-10-30 DOI: 10.1177/08971900241296638

Jessica W Skelley, Christopher J Rogers, English Gonzalez, Subin Kim, Adriane L York, Hannah Duncan, Fayth Morris

{"title":"Evaluation of Pharmacist-led Telehealth Medicare Annual Wellness Visits to Satisfy Quality Metrics and USPSTF Recommendations After Implementation of a Post-Visit Follow-Up Protocol.","authors":"Jessica W Skelley, Christopher J Rogers, English Gonzalez, Subin Kim, Adriane L York, Hannah Duncan, Fayth Morris","doi":"10.1177/08971900241296638","DOIUrl":"https://doi.org/10.1177/08971900241296638","url":null,"abstract":"Background: A Medicare Annual Wellness Visit (MAWV) serves Medicare patients by identifying and addressing gaps in preventive services and health screenings, often aligning with outpatient practice quality metrics. Objective: Evaluate an existing pharmacist-led MAWV telehealth service, determine the baseline quality metric satisfaction rate of telehealth MAWVs, and assess for improvement after implementing a post-MAWV follow-up protocol at a suburban, lower-income primary care clinic. Methods: This IRB-exempt, single-center retrospective chart review utilized the electronic health record at Christ Health Center, Birmingham, AL. From August 2020 through May 2022, 288 charts were assessed between 2 retrospective chart reviews that included patients 18 years or older with Medicare insurance and the ability to conduct a telehealth MAWV. The first chart review assessed metric and recommendation satisfaction within 12 months of the visit. The second chart review was performed after follow-up protocol implementation to assess for additional improvement within 3 months of the visit. Results: The percentage of MAWV recommendations completed groups after implementing a follow-up protocol. For the first chart review, 57.1% of the assessed Health Resources and Services Administration (HRSA), Uniform Data System (UDS) quality metrics, and Centers for Medicare and Medicaid Services (CMS)-required MAWV components were satisfied from the first chart review compared to 53.3% of satisfied quality metrics post-protocol implementation in spite of a substantially shorter follow-up timeframe. Conclusion: Telehealth MAWVs improve preventive care and quality metric satisfaction for Medicare patients. Post-visit follow-up protocols enhance satisfaction rates. Pharmacist-led MAWVs foster interprofessional collaboration and comprehensive patient care.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900241296638"},"PeriodicalIF":1.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142546087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessing Patient Feedback on the Feasibility of the YourRx Telepharmacy Mobile Application. 评估患者对 YourRx 远程药房移动应用程序可行性的反馈意见。

IF 1

Journal of pharmacy practice Pub Date : 2024-10-25 DOI: 10.1177/08971900241295286

Christine Veronica Misola, Zoe Nicolette Beatrice Oreta, Radha Kaur Lal, Maan Balt, Danica Resuello, Kevin Jace Miranda, Rogie Royce Carandang

{"title":"Assessing Patient Feedback on the Feasibility of the YourRx Telepharmacy Mobile Application.","authors":"Christine Veronica Misola, Zoe Nicolette Beatrice Oreta, Radha Kaur Lal, Maan Balt, Danica Resuello, Kevin Jace Miranda, Rogie Royce Carandang","doi":"10.1177/08971900241295286","DOIUrl":"https://doi.org/10.1177/08971900241295286","url":null,"abstract":"Background: Telepharmacy is a method utilized in pharmacy practice that delivers pharmaceutical care services via telecommunication technology. In the Philippines, the current process for patients to avail of telepharmacy services utilizes a variety of existing applications or websites instead of a single application. Objectives: This study aimed to assess patient feedback on the feasibility of the newly developed telepharmacy mobile application, YourRx. Specifically, it evaluated the application's functionality, usability, security, and performance. Methods: The study had 3 phases: (1) the design and development phase, (2) the implementation phase, wherein the pharmacists and patients were oriented beforehand with the use of YourRx mobile application, and (3) the evaluation phase, where the mobile application was evaluated for its functionality, usability, security, and performance by the patients through the use of a survey questionnaire and an interview. Results: YourRx application was developed and evaluated successfully. It is available for Android users and has primary features, including video calls, sharing, and setting an appointment. A total of 46 patients used the YourRx. Most of the patients were very satisfied with the navigation, service acquisition, and overall design of the YourRx. They expressed convenience in acquiring telepharmacy services because the application was easy to understand, use, and navigate. Conclusion: YourRx is a pioneering telepharmacy mobile application in the Philippines. The results of this study substantiate that YourRx is a user-friendly platform that provides patients convenient access to telepharmacy services with less time and effort thus improving patient health outcomes.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900241295286"},"PeriodicalIF":1.0,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142502622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Eco-Sustainability in Hospital Pharmacy: A Pilot Survey on 'Going Green'. 医院药房的生态可持续性：医院药房的生态可持续性："走向绿色 "试点调查。

IF 1

Journal of pharmacy practice Pub Date : 2024-10-24 DOI: 10.1177/08971900241295285

Ariane Blanc, Delphine Moulin, Jameason Cameron

{"title":"Eco-Sustainability in Hospital Pharmacy: A Pilot Survey on 'Going Green'.","authors":"Ariane Blanc, Delphine Moulin, Jameason Cameron","doi":"10.1177/08971900241295285","DOIUrl":"https://doi.org/10.1177/08971900241295285","url":null,"abstract":"Purpose: Between 2009 and 2015, the Canadian health care system was estimated to be responsible for 4.6% of national carbon emissions. Determine awareness of and describe eco-initiatives that the department of pharmacy can implement to aim to reduce the carbon footprint in hospital pharmacy in an effort to 'go green'. Methods: In a quality improvement initiative, pharmacy employees (i.e. pharmacists and pharmacy technicians) completed a cross-sectional survey designed to gauge willingness to 'go green' at work, to identify actionable areas of waste, and to assess commuting practices. Results: A total of 15 respondents completed the survey conducted March 14th -April 7th, 2022. Most respondents (73%) were willing to engage in more sustainable practices at work. The main barriers to implementing green practices at work were 'too time consuming' (20%), 'adds too much complexity' (20%), and 'cost' (16%). For commuting, 60% indicated the primary mode of transportation as 'personal vehicle', where 'subsidized transit' and was listed as the greatest incentive that could encourage a greener commute. The three largest areas of waste cited were 'single use plastic' (36%), 'limited of awareness of green practices' (15%), and 'lights left on in empty rooms' (12%). Conclusions: Pharmacy staff shared willingness to engage in more sustainable 'go green' practices but raised challenges to do so. With the knowledge that Canada has the second most climate intensive health system, there is a need for future research to describe how hospital pharmacies can contribute strategically to 'go green', advancing with implementing low carbon sustainable pharmacy practices.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900241295285"},"PeriodicalIF":1.0,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142502631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Great Expectations: Semaglutide as Antidiabetic Weight Management in a Psychiatric Hospital. 美好的期望：塞马鲁肽作为精神病院的抗糖尿病体重管理药物

IF 1

Journal of pharmacy practice Pub Date : 2024-10-22 DOI: 10.1177/08971900241294122

Krysta Shannon, Grace Shyh

引用次数: 0

Risk of Urinary Tract Infections in Male Veterans With Diabetes Prescribed Sodium-Glucose Cotransporter-2 Inhibitors Versus Sulfonylureas Across the Veterans Health Administration. 退伍军人健康管理局处方钠-葡萄糖转运体-2 抑制剂与磺脲类药物的男性退伍军人糖尿病患者尿路感染风险。

IF 1

Journal of pharmacy practice Pub Date : 2024-10-21 DOI: 10.1177/08971900241292692

Alyson Mathis, Matthew Lane, Jennifer Meyer Reid

{"title":"Risk of Urinary Tract Infections in Male Veterans With Diabetes Prescribed Sodium-Glucose Cotransporter-2 Inhibitors Versus Sulfonylureas Across the Veterans Health Administration.","authors":"Alyson Mathis, Matthew Lane, Jennifer Meyer Reid","doi":"10.1177/08971900241292692","DOIUrl":"https://doi.org/10.1177/08971900241292692","url":null,"abstract":"Background: Due to their mechanism of action, sodium-glucose cotransporter-2 inhibitors (SGLT2is) carry a presumed increased risk of urinary tract infection (UTI) which is reflected in current prescribing data. As SGLT2i prescribing trends increase, some retrospective studies confirm an increased risk of UTI while conflicting studies find no increased risk of UTI associated with this therapy. Objectives: This study aims to compare the odds of developing a UTI in male Veterans with type 2 diabetes mellitus (T2DM) on metformin taking a SGLT2i vs a sulfonylurea (SU) within the Veterans Health Administration (VHA). Methods: This retrospective cohort study identified male Veterans with T2DM on metformin with a new fill of SGLT2i or SU between January 1, 2020 to December 31, 2022. Patients were then assessed for UTI diagnosis. An adjusted odds ratio (AOR) was calculated. Results: The SGLT2i cohort had 5.2% of patients diagnosed with outpatient UTI and 1.6% of patients diagnosed with inpatient UTI. The SU cohort had 5.3% of patients diagnosed with outpatient UTI and 1.3% of patients diagnosed with inpatient UTI. A logistic regression analysis resulted in a decreased odds of diagnosis of outpatient UTI in the SGLT2i cohort vs the SU cohort ([AOR] = 0.91, 95% CI [0.86 - 0.96], P-value = < 0.001), and no difference in the diagnosis of inpatient UTI ([AOR] = 1.06, 95% CI [0.96 - 1.18], P-value = 0.234). Conclusion: This retrospective study of national VHA data adds to growing literature which finds no excessive risk of UTI associated with SGLT2i therapies.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900241292692"},"PeriodicalIF":1.0,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142468340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of Plasma-Lyte Versus Lactated Ringer's in Surgical Intensive Care Unit Trauma Patients as Fluid Resuscitation. 在外科重症监护室创伤患者的液体复苏中评估血浆-赖特与乳酸林格氏液的效果。

IF 1

Journal of pharmacy practice Pub Date : 2024-10-15 DOI: 10.1177/08971900241287854

Anna DeFrank, Shan Wang, Shahidul Islam, Kim Asmus, D'Andrea Joseph

{"title":"Evaluation of Plasma-Lyte Versus Lactated Ringer's in Surgical Intensive Care Unit Trauma Patients as Fluid Resuscitation.","authors":"Anna DeFrank, Shan Wang, Shahidul Islam, Kim Asmus, D'Andrea Joseph","doi":"10.1177/08971900241287854","DOIUrl":"https://doi.org/10.1177/08971900241287854","url":null,"abstract":"In critically ill patients, fluid resuscitation with balanced crystalloids close to plasma osmolarity have a lower risk of electrolyte imbalances and demonstrated better clinical outcomes compared to normal saline (NS). While lactated ringer's (LR) has shown benefit over NS, plasma-lyte (PL) with a higher osmolarity and different electrolyte formulation is hypothesized to be superior. We performed a retrospective observational cohort study over 37 months at a tertiary hospital. Inclusion criteria were hospitalization in the surgical intensive care unit (SICU), trauma indication, ≥18 years old, and received either PL or LR. All PL administrations and every fifth patient with LR as resuscitation were included in order to match the sample size in each group. Primary outcomes were SICU length of stay (LOS), hospital LOS, and mortality. Secondary outcomes were biomarker changes from baseline. There were 113 patients in both PL and LR groups. The PL arm had higher APACHE II scores (16 vs 13, P = .033) and were more likely ventilated (39.3% vs 20.4%, P = .002) compared to LR. Median hospital LOS (12.0 vs 8.0, P < .001) and SICU LOS (6.0 vs 3.0, P < .001) are significantly longer in PL group compared to the LR group. However, there was no difference in in-hospital mortality (5.3% vs 3.5% P = .519) and SICU mortality (9.7% vs 5.3%, P > .208) between PL and LR. Overall, PL use was associated with prolonged hospital and SICU LOS. PL use did not demonstrate mortality benefit. However, patients were more critically ill in PL group based on higher APACHE II scores and higher rates of mechanical ventilation, which could be contributing to these unfavorable outcomes.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900241287854"},"PeriodicalIF":1.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142468339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiovascular Safety of Amphetamine/Dextroamphetamine versus Methylphenidate in Older Adults. 安非他明/去甲安非他明与哌醋甲酯在老年人心血管中的安全性对比。

IF 1

Journal of pharmacy practice Pub Date : 2024-10-01 Epub Date: 2024-01-18 DOI: 10.1177/08971900241229111

Rachel Paulmann, Randi Stouffer, Monica Mathys, Rick Weideman, Carlos Alvarez, Hui Yang

{"title":"Cardiovascular Safety of Amphetamine/Dextroamphetamine versus Methylphenidate in Older Adults.","authors":"Rachel Paulmann, Randi Stouffer, Monica Mathys, Rick Weideman, Carlos Alvarez, Hui Yang","doi":"10.1177/08971900241229111","DOIUrl":"10.1177/08971900241229111","url":null,"abstract":"Background: Recent epidemiological data has shown a sharp increase in stimulant use among older adults, which is notable as older adults may be especially vulnerable to their cardiovascular effects. Results of recent studies have shown an increase in cardiovascular events among older adults using stimulants; however, little data exists comparing cardiovascular safety of these agents head-to-head. Objective: To determine if the incidence of serious cardiovascular events, including myocardial infarction (MI), stroke/transient ischemic attack (TIA), or arrhythmia, are different in patients taking amphetamine/dextroamphetamine compared with patients taking methylphenidate. Methods: Retrospective chart review of veterans 50 years and older at the Veterans Affairs North Texas Health Care System (VANTHCS) who were first prescribed a stimulant between 2015 and 2021. The primary outcome was the difference in composite cardiovascular events between amphetamine/dextroamphetamine and methylphenidate. Secondary outcomes were the composite cardiovascular endpoints compared individually (MI, stroke/TIA, or arrhythmia). Hazard ratios were calculated based off of a time-to-event analysis displayed using a Kaplan-Meier curve for primary and secondary outcomes. Results: 466 veterans were screened for inclusion, 30 were excluded, and 436 were included. There was no difference found in composite cardiovascular events between the 241 veterans in the amphetamine/dextroamphetamine group and the 195 veterans in the methylphenidate group with 12 (5%) vs 8 (4.1%) events respectively (P = .6635). There was also no difference in time-to-event analysis (P = .4966). Conclusion: In elderly veterans, there was no difference found in incidence of major cardiovascular events with the use of amphetamine/dextroamphetamine compared with methylphenidate.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"1116-1120"},"PeriodicalIF":1.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139491672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hemostatic Efficacy and Safety of Weight-Based Versus Fixed-Dose 4F-PCC for Vitamin K Antagonist Reversal. 基于体重的 4F-PCC 与固定剂量的 4F-PCC 用于维生素 K 拮抗剂逆转的止血效果和安全性。

IF 1

Journal of pharmacy practice Pub Date : 2024-10-01 Epub Date: 2024-01-19 DOI: 10.1177/08971900241228779

Ashley E Milkovits, David Sugrue, Janie Faris, Jessica L Schad, Kelly B McAllister

{"title":"Hemostatic Efficacy and Safety of Weight-Based Versus Fixed-Dose 4F-PCC for Vitamin K Antagonist Reversal.","authors":"Ashley E Milkovits, David Sugrue, Janie Faris, Jessica L Schad, Kelly B McAllister","doi":"10.1177/08971900241228779","DOIUrl":"10.1177/08971900241228779","url":null,"abstract":"Background: Four-factor prothrombin complex concentrate (4F-PCC) is indicated for vitamin K antagonist (VKA) reversal but is associated with thrombotic events (TE). In 2018, the institution revised 4F-PCC dosing for VKA reversal from INR and weight-based dosing to a fixed-dose of 1500 units. Objective: The purpose of this study was to compare hemostatic efficacy and TE rate of fixed-dose 4PCC to weight-based dosing. Methods: This was a retrospective, single-center, quasi-experimental study of adult patients who received 4F-PCC for VKA reversal from January 2014 through May 2016 (INR and weight-based dosing) or April through October 2018 (fixed-dosing). The primary endpoint was hemostatic efficacy, defined by achieving an INR of ≤1.4, or an INR of ≤1.7 with evidence of hemostasis. The key secondary endpoint was TE within 14 days of 4F-PCC administration. Data were analyzed using descriptive statistics, chi-squared for nominal data and Mann-Whitney U for ordinal and continuous data. Results: The study included 163 patients who received weight-based dosing and 45 who received fixed-dose 4F-PCC. Hemostatic efficacy was 76.9% of patients in the weight-based group and 77.4% of patients in the fixed-dose group (P = .229). TE occurred in 13.5% of the weight-based vs 6.7% of the fixed-dose group (P = .181). Conclusion: This study found no difference in hemostatic efficacy with fixed-dose 4F-PCC for VKA reversal compared to INR and weight-based dosing. The occurrence of TE was reduced by 50% with the 4F-PCC fixed-dose strategy; however, this difference was not statistically significant. Further randomized studies are needed to confirm these results.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"1099-1106"},"PeriodicalIF":1.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139502480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk of Urinary Infections in Veterans on Empagliflozin With Concurrent Catheter Use. 同时使用导尿管的 Empagliflozin 退伍军人的泌尿系统感染风险。

IF 1

Journal of pharmacy practice Pub Date : 2024-10-01 Epub Date: 2024-01-19 DOI: 10.1177/08971900241229107

Rachel A Hopper, Danni M McMahan, Kathryn A Jarvis, Rick A Weideman

{"title":"Risk of Urinary Infections in Veterans on Empagliflozin With Concurrent Catheter Use.","authors":"Rachel A Hopper, Danni M McMahan, Kathryn A Jarvis, Rick A Weideman","doi":"10.1177/08971900241229107","DOIUrl":"10.1177/08971900241229107","url":null,"abstract":"There has been concern over whether to use sodium-glucose-cotransporter-2 (SGLT-2) inhibitors in patients that use catheters due to the concern for increased urinary tract infections (UTIs). The concern is that patients who use catheters are already at an increased risk for UTIs and that SGLT-2-inhibitors may promote bacterial growth due their mechanism of action, ie. increasing glycosuria. The objective of this study was to evaluate whether using empagliflozin, a SGLT-2-inhibitor, in patients who also use catheters, increases their risks for UTIs. A retrospective chart review of electronic health records at a single-center was completed of all Veterans who received an empagliflozin prescription and were also using catheters between October 1, 2015 and September 30, 2022. Veterans were included if they were using catheters for at least 2 months prior to starting empagliflozin and were on both therapies for at least 2 months concurrently. The primary outcome for this study is the number of UTIs occurring prior to and after beginning empagliflozin treatment. Additional secondary outcomes included change in A1c, change in body mass index (BMI), UTI-hospitalizations, and fungal infections. Of the 91 patients with concurrent empagliflozin and catheter-use, only 25 Veterans were included. There was an occurrence of .09 UTIs/month pre-empagliflozin compared to .07 post-empagliflozin (P = .61). There was an observed trend in Veterans with Type 2 Diabetes having an increased rate of UTIs. There was no statistically significant difference found in UTI rates when comparing catheters alone to concurrent catheter and empagliflozin-use.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"1127-1131"},"PeriodicalIF":1.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139502484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0